News & Updates
Filter by Specialty:
Thrombectomy a viable first-line therapy for stroke in pregnant women, new mothers
In the treatment of women with acute ischaemic stroke, mechanical thrombectomy is effective and can be safely performed during pregnancy or the postpartum period, as shown in a study.
Thrombectomy a viable first-line therapy for stroke in pregnant women, new mothers
05 Oct 2021Delgocitinib ointment safely reduces symptoms in paediatric atopic dermatitis
Treatment with delgocitinib ointment, a topical Janus kinase (JAK) inhibitor, for paediatric atopic dermatitis (AD) is effective and well tolerated when applied for up to 56 weeks, according to a phase III trial and a subsequent open-label, long-term study in Japan.
Delgocitinib ointment safely reduces symptoms in paediatric atopic dermatitis
05 Oct 2021Oteseconazole bests fluconazole for vaginal yeast infections
Oteseconazole (VT-1161), a novel investigational fungal CYP51 inhibitor, outdid fluconazole/placebo for managing acute and recurrent* vulvovaginal candidiasis (VVC), according to data from the phase III ultraVIOLET trial.
Oteseconazole bests fluconazole for vaginal yeast infections
05 Oct 2021HCC in SG: NASH aetiology on the rise, curative therapy more accessible
Hepatocellular carcinoma (HCC) in Singapore has changed markedly throughout the last decade, with patients being diagnosed at an increasingly older age and cryptogenic cirrhosis/nonalcoholic steatohepatitis (NASH) becoming a more important aetiology, according to a recent study.
HCC in SG: NASH aetiology on the rise, curative therapy more accessible
05 Oct 2021Leuprolide acetate maintains QOL scores in prostate cancer patients despite worsening condition
Treatment with leuprolide acetate every 6 months does not elicit significant changes in health-related quality of life (HRQOL) among prostate cancer (PC) patients despite substantial deterioration of body and role functions, a recent study has found.
Leuprolide acetate maintains QOL scores in prostate cancer patients despite worsening condition
05 Oct 2021Vedolizumab yields sustained improvements in fistulizing Crohn’s disease
Intravenous dosing regimens of vedolizumab appear to favourably alter outcomes in patients with fistulizing Crohn’s disease, according to data from the phase IV ENTERPRISE trial.